Olema Pharmaceuticals closed a public offering of 11.5 million shares, raising approximately $218.5 million for breast cancer therapies.
Quiver AI Summary
Olema Pharmaceuticals, Inc. has announced the successful closing of its public offering of 11.5 million shares of common stock at $19.00 per share, raising approximately $218.5 million before expenses. This includes the full exercise of the underwriters' option for an additional 1.5 million shares. The offering was conducted under a previously filed shelf registration statement and was managed by several firms, including TD Cowen and Evercore ISI. Olema, based in San Francisco, focuses on developing targeted therapies for breast cancer, with its lead candidate, palazestrant, currently in two Phase 3 trials. The company is also developing another treatment, OP-3136, in a Phase 1 study.
Potential Positives
- Olema Pharmaceuticals successfully closed a public offering of 11,500,000 shares, securing gross proceeds of approximately $218.5 million, which strengthens its financial position.
- The offering included the full exercise of underwriters’ option to purchase additional shares, indicating strong demand for Olema's stock.
- The funds raised will support the advancement of Olema’s clinical pipeline, including its lead product candidate, palazestrant, which is already in Phase 3 trials.
Potential Negatives
- Closing an underwritten public offering may indicate the company requires additional capital, which could raise concerns about financial stability or the sustainability of current operations.
- The offering priced at $19.00 per share might reflect a lower valuation than expected, potentially signaling a lack of investor confidence in the company's future growth prospects.
- The company is in clinical stages for its lead product, which may imply that it has not yet reached commercialization, adding uncertainty about future revenue streams.
FAQ
What recent financial event did Olema Pharmaceuticals announce?
Olema Pharmaceuticals announced the closing of its underwritten public offering of 11,500,000 shares of common stock.
How much did Olema Pharmaceuticals raise from the public offering?
Olema raised approximately $218.5 million from the public offering before deductions.
Who were the book-running managers for the Olema offering?
The book-running managers included TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer & Co., and H.C. Wainwright & Co.
What is Olema's lead product candidate?
Olema's lead product candidate is palazestrant (OP-1250), an orally available complete estrogen receptor antagonist.
Where can I access the final prospectus for the Olema offering?
The final prospectus can be accessed for free through the SEC’s website at www.sec.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- CYRUS HARMON has made 0 purchases and 4 sales selling 25,000 shares for an estimated $204,840.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OLMA Hedge Fund Activity
We have seen 60 institutional investors add shares of $OLMA stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC removed 2,378,762 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,288,079
- WOODLINE PARTNERS LP removed 1,288,000 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $12,609,519
- MILLENNIUM MANAGEMENT LLC removed 939,636 shares (-73.9%) from their portfolio in Q3 2025, for an estimated $9,199,036
- SILVERARC CAPITAL MANAGEMENT, LLC added 933,541 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,139,366
- KINGDON CAPITAL MANAGEMENT, L.L.C. added 854,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,360,659
- BALYASNY ASSET MANAGEMENT L.P. added 693,179 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,786,222
- SOLEUS CAPITAL MANAGEMENT, L.P. added 619,874 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,068,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Oppenheimer issued a "Outperform" rating on 11/18/2025
- Guggenheim issued a "Buy" rating on 10/08/2025
- Citigroup issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 5 analysts offer price targets for $OLMA in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $32.0 on 11/18/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $36.0 on 11/18/2025
- Matthew Biegler from Oppenheimer set a target price of $45.0 on 11/18/2025
- Brad Canino from Guggenheim set a target price of $20.0 on 10/08/2025
- Yigal Nochomovitz from Citigroup set a target price of $21.0 on 08/12/2025
Full Release
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,500,000 additional shares of common stock, at a price to the public of $19.00 per share. The gross proceeds to Olema from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $218.5 million.
TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer & Co. and H.C. Wainwright & Co. acted as book-running managers for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the “SEC”) on January 6, 2025 and declared effective on January 15, 2025, and a related registration statement on Form S-3MEF that was filed with the SEC pursuant to Rule 462(b) on November 18, 2025, which became automatically effective on November 18, 2025. Copies of the final prospectus supplement and accompanying prospectus relating to the offering can be accessed at no charge through the SEC’s website at www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective ER degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
